Corticosteroid Exposure Affects Bone Health in Asthma Patients
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
Osteoporosis
Osteoporotic Fracture Risk Lower for DOAC Than Warfarin in A-Fib
No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants
Societies Issue Joint Guidance for Osteoporosis Management During the COVID-19 Pandemic
A coalition of experts representing multiple medical societies issued guidance on the management of osteoporosis during the COVID-19 pandemic.
Endocrine Society Updates Postmenopausal Osteoporosis Management Guidelines to Include Romosozumab
The Endocrine Society has issued an update to the organization’s 2019 clinical practice guideline on pharmacologic management of osteoporosis to include romosozumab.
Fracture Risk, BMD Improvement With Abaloparatide Plus Alendronate in Osteoporosis, OA
In this post hoc analysis, researchers evaluated the efficacy and safety of abaloparatide followed by alendronate vs placebo followed by alendronate in a subgroup of patients with osteoarthritis.
Experimental Growth Factor May Aid Knee Osteoarthritis
However, clinical significance uncertain as patients did not report symptom improvement
New Treatment Approved for Osteoporosis
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.
Does Osteoporosis Treatment Reduce Overall Mortality in Addition to Fracture Risk?
According to a recent meta-analysis, no significant association was observed between pharmacotherapies used for osteoporosis treatment and mortality rate, despite previous studies suggesting the treatments, particularly bisphosphonates, lower overall mortality. To investigate this association, study authors searched various databases and conference abstracts for randomized placebo-controlled studies in which drug therapies were evaluated for a year…
Romosozumab Shows Positive Bone Formation Results in Study
Lower values for resorption end points at month two persisted to month 12, indicating reduced turnover
Triclosan Exposure May Lower Bone Mineral Density in Women
Osteoporosis in intertrochanter more likely in women with high urinary triclosan concentration.
